Interventions for preventing weight gain after smoking cessation
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most people who stop smoking gain weight, on average about 7 kg in the long term. There are some interventions that have been specifically designed to tackle smoking cessation whilst also limiting weight gain. Many smoking cessation pharmacotherapies and other interventions may also limit weight gain. OBJECTIVES: This review is divided into two parts. (1) Interventions designed specifically to aid smoking cessation and limit post-cessation weight gain (2) Interventions designed to aid smoking cessation that may also plausibly have an effect on weight SEARCH STRATEGY: Part 1: We searched the Cochrane Tobacco Addiction Group's Specialized Register which includes trials indexed in MEDLINE, EMBASE, SciSearch and PsycINFO, and other reviews and conference abstracts. Part 2: We searched the included studies of Cochrane smoking cessation reviews of nicotine replacement therapy, antidepressants, nicotine receptor partial agonists, cannabinoid type 1 receptor antagonists (rimonabant), and exercise interventions, published in Issue 4, 2008 of The Cochrane Library. SELECTION CRITERIA: Part 1: We included trials of interventions designed specifically to address both smoking cessation and post-cessation weight gain that had measured weight at any follow-up point and/or smoking six months or more after quitting.Part 2: We included trials from the selected Cochrane reviews that could plausibly modify post-cessation weight gain if they had reported weight gain by trial arm at end of treatment or later. DATA COLLECTION AND ANALYSIS: We extracted data in duplicate on smoking and weight for part 1 trials, and on weight only for part 2. Abstinence from smoking is expressed as a risk ratio (RR), using the most rigorous definition of abstinence available in each trial, and biochemically validated rates if available. The outcome is expressed as the difference in weight change between trial arms from baseline. Where appropriate, we performed meta-analysis using the Mantel-Haenszel method for smoking and inverse variance for weight using a fixed-effect model. MAIN RESULTS: We found evidence that pharmacological interventions aimed at reducing post-cessation weight gain resulted in a significant reduction in weight gain at the end of treatment (dexfenfluramine (-2.50kg [-2.98kg to -2.02kg], fluoxetine (-0.80kg [-1.27kg to -0.33kg], phenylpropanolamine (PPA) (-0.50kg [-0.80kg to -0.20kg], naltrexone (-0.76kg [-1.51kg to -0.01kg])). No evidence of maintenance of the treatment effect was found at six or 12 months.Among the behavioural interventions, only weight control advice was associated with no reduction in weight gain and with a possible reduction in abstinence. Individualized programmes were associated with reduced weight gain at end of treatment and at 12 months (-2.58kg [-5.11kg to -0.05kg]), and with no effect on abstinence (RR 0.74 [0.39 to 1.43]). Very low calorie diets (-1.30kg (-3.49kg to 0.89kg] at 12 months) and cognitive behavioural therapy (CBT) (-5.20kg (-9.28kg to -1.12kg] at 12 months) were both associated with improved abstinence and reduced weight gain at end of treatment and at long-term follow up.Both bupropion (300mg/day) and fluoxetine (30mg and 60mg/day combined) were found to limit post-cessation weight gain at the end of treatment (-0.76kg [-1.17kg to -0.35kg] I(2)=48%) and -1.30kg [-1.91kg to -0.69kg]) respectively. There was no evidence that the weight reducing effect of bupropion was dose-dependent. The effect of bupropion at one year was smaller and confidence intervals included no effect (-0.38kg [-2.001kg to 1.24kg]).We found no evidence that exercise interventions significantly reduced post-cessation weight gain at end of treatment but evidence for an effect at 12 months (-2.07kg [-3.78kg, -0.36kg]).Treatment with NRT resulted in attenuation of post-cessation weight gain (-0.45kg [-0.70kg, -0.20kg]) at the end of treatment, with no evidence that the effect differed for different forms of NRT. The estimated weight gain reduction was similar at 12 months (-0.42kg [-0.92kg, 0.08kg]) but the confidence intervals included no effect.There were no relevant data on the effect of rimonabant on weight gain.We found no evidence that varenicline significantly reduced post-cessation weight gain at end of treatment and no follow-up data are currently available. One study randomizing successful quitters to 12 more weeks of active treatment showed weight to be reduced by 0.71kg (-1.04kg to -0.38kg). In three studies, participants taking bupropion gained significantly less weight at the end of treatment than those on varenicline (-0.51kg [-0.93kg to -0.09kg]). AUTHORS' CONCLUSIONS: Behavioural interventions of general advice only are not effective and may reduce abstinence. Individualized interventions, very low calorie diets, and CBT may be effective and not reduce abstinence. Exercise interventions are not associated with reduced weight gain at end of treatment, but may be associated with worthwhile red
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub3 · Cited by 721
Tonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Smoking cessation and weight gain
Filozof, C., Fernández Pinilla, M. C., & Fernández‐Cruz, A. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00131.x · Cited by 519
Nides, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1561 · Cited by 390
The Efficacy of Exercise as an Aid for Smoking Cessation in Women: A Randomized Controlled Trial
Marcus, B. H., Albrecht, A. E., King, T. K., Parisi, A. F., Pinto, B. M., Roberts, M., Niaura, R. S., & Abrams, D. B. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.11.1229 · Cited by 384
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Efficacy of a nicotine lozenge for smoking cessation
Shiffman, S., Dresler, C. M., Hajek, P., Gilburt, S. J. A., Targett, D. A., & Strahs, K. R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.11.1267 · Cited by 265
Tonnesen (1999) · doi:10.1034/j.1399-3003.1999.13b04.x · Cited by 260
Tonstad, S. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00003-4 · Cited by 246
Perkins, K. A., Marcus, M. D., Levine, M. D., D'Amico, D., Miller, A., Broge, M., Ashcom, J., & Shiffman, S. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.4.604 · Cited by 214
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110073920 · Cited by 191
A double-blind study evaluating the long-term safety of varenicline for smoking cessation
Williams, K. E., Reeves, K. R., Billing, C. B., Pennington, A. M., & Gong, J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182185 · Cited by 184
Bupropion for Smoking Cessation
Dale, L. C., Glover, E. D., Sachs, D. P. L., Schroeder, D. R., Offord, K. P., Croghan, I. T., & Hurt, R. D. (2001) · Chest · doi:10.1378/chest.119.5.1357 · Cited by 177
Lerman, C., Kaufmann, V., Rukstalis, M., Patterson, F., Perkins, K., Audrain-McGovern, J., & Benowitz, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-6-200403160-00009 · Cited by 110
Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers
Gourlay, S. G., Forbes, A., Forbes, A., Marriner, T., Pethica, D., & McNeil, J. J. (1995) · BMJ · doi:10.1136/bmj.311.7001.363 · Cited by 104
Bupropion for Smoking Cessation: A Randomized Trial
Simon, J. A., Duncan, C., Carmody, T. P., & Hudes, E. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.16.1797 · Cited by 81
Shiffman, S., Dresler, C. M., & Rohay, J. M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00576.x · Cited by 54
Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial
Cook, J. W., Spring, B., McChargue, D. E., Borrelli, B., Hitsman, B., Niaura, R., Keuthen, N. J., & Kristeller, J. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1711-8 · Cited by 46
Cited by
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Interventions for promoting smoking cessation during pregnancy
Lumley, J., Chamberlain, C., Dowswell, T., Oliver, S., Oakley, L., & Watson, L. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001055.pub3 · Cited by 890
Interventions for promoting smoking cessation during pregnancy
Lumley, J., Oliver, S., Chamberlain, C., & Oakley, L. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001055.pub2 · Cited by 622
Cigarette Smoking, Nicotine, and Body Weight
Audrain-McGovern, J., & Benowitz, N. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.105 · Cited by 571
Interventions for preventing weight gain after smoking cessation
Farley, A. C., Hajek, P., Lycett, D., & Aveyard, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006219.pub3 · Cited by 334
Self-citation
Metadata
- Authors
- Parsons, A. C., Shraim, M., Inglis, J., Aveyard, P., & Hajek, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2009-01-21
- Issue
- 1
- Pages
- CD006219-CD006219
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4237120463
- Cited by
- 95
- References
- 23
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.